Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.
Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin.
Tomlinson
Brian
B
The Chinese University of Hong Kong, Division of Clinical Pharmacology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China. btomlinson@cuhk.edu.hk
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003072:Cognition Disorders / Q000188:drug therapy; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D013007:Growth Hormone-Releasing Hormone / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity / Q000031:analogs & derivatives; D019247:HIV Wasting Syndrome / Q000188:drug therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy; D006620:Hip Fractures / Q000188:drug therapy; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D010455:Peptides / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D011994:Recombinant Proteins / Q000627:therapeutic use; D012893:Sleep Wake Disorders / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000276:Adjuvants, Immunologic; D010455:Peptides; D011994:Recombinant Proteins; D013007:Growth Hormone-Releasing Hormone; C479538:tesamorelin